Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin

Although several studies have shown that the serum levels of osteoprotegerin (OPG) are significantly elevated in patients affected with atherosclerotic lesions in coronary and peripheral arteries, the cellular source and the role of OPG in the physiopathology of atherosclerosis are not completely defined. Therefore, we aimed to investigate the potential contribution of mesenchymal stem cells in the production/release of OPG. OPG was detectable by immunohistochemistry in aortic and coronary atherosclerotic plaques, within or in proximity of intimal vascular smooth muscle cells (SMC). In addition, bone marrow mesenchymal stem cell (MSC)-derived vascular SMC as well as primary aortic SMC released in the culture supernatant significantly higher levels of OPG with respect to MSC-derived endothelial cells (EC) or primary aortic EC. On the other hand, in vitro exposure to full-length human recombinant OPG significantly increased the proliferation rate of aortic SMC cultures, as monitored by bromodeoxyuridine incorporation. Taken together, these data suggest that OPG acts as an autocrine/paracrine growth factor for vascular SMC, which might contribute to the progression of atherosclerotic lesions.Key words: osteoprotegerin, mesenchymal stem cells, smooth muscle cells, atherosclerosis.A therosclerosis is a form of chronic low-grade inflammation resulting from interaction between modified lipoproteins, monocyte-derived macrophages and vascular smooth muscle cells (SMC) (Libby, 2002). Although the prevalent view is that intimal vascular SMC found in atherosclerotic plaques derive from cells migrating from the tunica media of the same artery (Libby, 2002), accumulating data indicate that also bone marrow (BM) mesenchymal stem cells (MSC), also known as multipotent stromal cells, have the potential to migrate in sites of vascular injury or inflammation and to differentiate into vascular SMC (Hillebrands et al., 2001, Li et al., 2001).Several studies have clearly demonstrated that the serum levels of the soluble member of the TNF-receptor super-family osteoprotegerin (OPG) are elevated in patients with coronary or carotid artery disease, especially those with clinically unstable atherosclerotic plaques (Jono et al., 2002, Schoppet et al., 2003, Secchiero et al., 2006a, Shin et al., 2006, Abedin et al., 2007, Avignon et al., 2007, Gulbiken et al., 2007, Kadoglu et al., 2008a, Omland et al., 2008). Despite the fact that neither the cellular source nor the physiological and pathological effects of elevated serum levels of OPG are well understood, a possible pathogenic link between elevated levels of OPG and inflammation has been suggested by recent in vitro studies of our and others research groups (Zauli et al., 2007, Mangan et al. 2007).Therefore, in order to assess the potential contribution of MSC in the pathogenesis of atherosclerosis, we have evaluated the release of OPG in the culture supernatants of BM-derived MSC differentiating along the vascular SMC or endothelial cell (EC) lineages. In addition, we have investigated the effect of recombinant human OPG on aortic SMC proliferation.